Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FBP1 | P09467 | 2/20 | 0.58 |
| ▸ | AMDHD2 | Q9Y303 | 1/20 | 0.47 |
| ▸ | IGF2R | P11717 | 4/20 | 0.44 |
| ▸ | PYGB | P11216 | 6/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | UMPS | P11172 | 1/20 | 0.41 |
| ▸ | ATIC | P31939 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13176653 | 1.00 | FBP1 (0.58) | FBP1AMDHD2IGF2RPYGBGAA | |
| SCHEMBL4366341 | 1.00 | FBP1 (0.58) | FBP1AMDHD2IGF2RPYGBGAA | |
| SCHEMBL851442 | 1.00 | FBP1 (0.58) | FBP1AMDHD2IGF2RPYGBGAA | |
| SCHEMBL30630944 | 0.92 | FBP1 (0.49) | FBP1AMDHD2IGF2RPYGBGAA | |
| SCHEMBL29366110 | 0.85 | FBP1 (0.62) | FBP1AMDHD2IGF2RPYGBUMPS | |
| SCHEMBL16492065 | 0.85 | FBP1 (0.62) | FBP1AMDHD2IGF2RPYGBUMPS | |
| SCHEMBL4362008 | 0.81 | FBP1 (0.53) | FBP1AMDHD2IGF2RPYGBGAA | |
| SCHEMBL4362015 | 0.81 | FBP1 (0.53) | FBP1AMDHD2IGF2RPYGBGAA | |
| SCHEMBL849806 | 0.81 | FBP1 (0.53) | FBP1AMDHD2IGF2RPYGBGAA | |
| SCHEMBL13176580 | 0.81 | FBP1 (0.53) | FBP1AMDHD2IGF2RPYGBGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 100 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250129088-A1 | CEREBLON E3 UBIQUITIN LIGASE INHIBITOR | GAN & LEE PHARMACEUTICALS CO., LTD. (CN) | 2025-04-24 | — | — | US | claimed |
| US-20260138981-A1 | DIHYDROFOLATE REDUCTASE INHIBITORS FOR ANTI-BIOTIC RESISTANT INFECTIONS | THE TRUSTEES OF PRINCETON UNIV (US) | 2026-05-21 | — | — | US | disclosed |
| US-20260130855-A1 | GAMMA POLYGLUTAMATED ANTIFOLATES AND USES THEREOF | L E A F HOLDINGS GROUP LLC (US) | 2026-05-14 | — | — | US | disclosed |
| US-20260053806-A1 | GAMMA POLYGLUTAMATED METHOTREXATE AND USES THEREOF | L E A F HOLDINGS GROUP LLC (US) | 2026-02-26 | — | — | US | disclosed |
| US-12558007-B2 | In vivo enzyme activity sensors and methods | ABBOTT DIABETES CARE INC. (US) | 2026-02-24 | — | — | US | disclosed |
| US-20260048054-A1 | ALPHA POLYGLUTAMATED TETRAHYDROFOLATES AND USES THEREOF | L E A F HOLDINGS GROUP LLC (US) | 2026-02-19 | — | — | US | disclosed |
| US-20250319123-A1 | GAMMA POLYGLUTAMATED ANTIFOLATES AND USES THEREOF | L E A F HOLDINGS GROUP LLC (US) | 2025-10-16 | — | — | US | disclosed |
| US-20250319188-A1 | ALPHA POLYGLUTAMATED ANTIFOLATES AND USES THEREOF | L E A F HOLDINGS GROUP LLC (US) | 2025-10-16 | — | — | US | disclosed |
| US-12433893-B2 | Alpha polyglutamated pemetrexed and uses thereof | L.E.A.F. HOLDINGS GROUP LLC (US) | 2025-10-07 | — | — | US | disclosed |
| US-20250222001-A1 | GAMMA POLYGLUTAMATED METHOTREXATE AND USES THEREOF | L.E.A.F. HOLDINGS GROUP LLC | 2025-07-10 | — | — | US | disclosed |
| WO-2022112509-A1 | GENETICALLY ENGINEERED BACTERIUM CAPABLE OF PRODUCING CYTOKININS WITH ISOPRENOID SIDE CHAINS | ACIES BIO D.O.O. (SI) | 2022-06-02 | — | — | WO | disclosed |
| EP-4006139-A1 | GENETICALLY ENGINEERED BACTERIUM CAPABLE OF PRODUCING CYTOKININS WITH ISOPRENOID SIDE CHAINS | Acies Bio d.o.o. (SI) | 2022-06-01 | — | — | EP | disclosed |
| US-11344628-B2 | Alpha polyglutamated antifolates and uses thereof | L.E.A.F. HOLDINGS GROUP LLC (US) | 2022-05-31 | — | — | US | disclosed |
| CN-114555127-A | Method for preparing polyglutamated antifolates and use of compositions thereof | L.E.A.F.控股集团公司 | 2022-05-27 | — | — | CN | disclosed |
| US-20220160712-A1 | METHODS OF TREATING RHEUMATOID ARTHRITIS AND FOR PREDICTING THE RESPONSE TO METHOTREXATE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2022-05-26 | — | — | US | disclosed |
| US-11293018-B2 | Manipulation of nuclear architecture | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2022-04-05 | — | — | US | disclosed |
| US-20220088220-A1 | GAMMA-D POLYGLUTAMATED PEMETREXED AND USES THEREOF | L.E.A.F. HOLDINGS GROUP PLLC | 2022-03-24 | — | — | US | disclosed |
| US-20220088218-A1 | GAMMA-D POLYGLUTAMATED PEMETREXED AND USES THEREOF | L.E.A.F. HOLDINGS GROUP LLC | 2022-03-24 | — | — | US | disclosed |
| US-20220088219-A1 | ALPHA POLYGLUTAMATED PEMETREXED AND USES THEREOF | L.E.A.F. HOLDINGS GROUP PLLC | 2022-03-24 | — | — | US | disclosed |
| US-20090186358-A1 | Pathway Analysis of Cell Culture Phenotypes and Uses Thereof | WYETH (US) | 2009-07-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250129088-A1 | CEREBLON E3 UBIQUITIN LIGASE INHIBITOR | CRBN, UBE3A, UBE3C | FBP1 3525/4885AMDHD2 4336/4885IGF2R 2095/4885 |
| US-12433893-B2 | Alpha polyglutamated pemetrexed and uses thereof | FPGS, PML, MTHFD1 | FBP1 1593/4885AMDHD2 3301/4885IGF2R 2879/4885 |
| US-20250319123-A1 | GAMMA POLYGLUTAMATED ANTIFOLATES AND USES THEREOF | GGCT, IFNG, FPGS | FBP1 1682/4885AMDHD2 2299/4885IGF2R 3653/4885 |
| US-20260138981-A1 | DIHYDROFOLATE REDUCTASE INHIBITORS FOR ANTI-BIOTIC RESISTANT INFECTIONS | DHFR, CBR1, DHRS9 | FBP1 463/4885AMDHD2 1297/4885IGF2R 605/4885 |
| US-20260048054-A1 | ALPHA POLYGLUTAMATED TETRAHYDROFOLATES AND USES THEREOF | FOLR2, FOLR1, FPGS | FBP1 299/4885AMDHD2 3060/4885IGF2R 1983/4885 |
| US-20250319188-A1 | ALPHA POLYGLUTAMATED ANTIFOLATES AND USES THEREOF | FPGS, GGCT, FOLR1 | FBP1 1217/4885AMDHD2 2178/4885IGF2R 3648/4885 |
| US-20250222001-A1 | GAMMA POLYGLUTAMATED METHOTREXATE AND USES THEREOF | IFNG, FPGS, MTX1 | FBP1 3550/4885AMDHD2 2689/4885IGF2R 2671/4885 |
| US-20260053806-A1 | GAMMA POLYGLUTAMATED METHOTREXATE AND USES THEREOF | FPGS, PDF, STOML2 | FBP1 3859/4885AMDHD2 4412/4885IGF2R 2501/4885 |
| US-20260130855-A1 | GAMMA POLYGLUTAMATED ANTIFOLATES AND USES THEREOF | FOLR2, FPGS, FOLR1 | FBP1 496/4885AMDHD2 3800/4885IGF2R 2454/4885 |
| US-12558007-B2 | In vivo enzyme activity sensors and methods | ACHE, CHAT, BCHE | FBP1 2680/4885AMDHD2 84/4885IGF2R 2850/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.